Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Cytotherapy. 2010 Oct;12(6):807–817. doi: 10.3109/14653249.2010.491821

Figure 2.

Figure 2

Inhibition of p38MAPK results in a 2.1-fold increase in total number of αMHC+ hCM. Single-cell suspensions of SB203580-treated (p38i) and untreated (Ctl) hEB differentiated for 30 days were analyzed by flow cytometry for the expression of αMHC. Isotype control antibody was used to set the positive gate (left). SB203580-treated samples demonstrated a 2.1-fold increase (26.3% versus 12.3%; P < 0.01) in the number of αMHC+ hCM compared with untreated cells. Representative data are shown (n = 3). FSC, forward light scatter.